Screener
Avalo Therapeutics AVTX Shares (Diluted)
Shares (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Avalo Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.
The source filing: Avalo Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:03 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001534120-26-000049
| Line item | Three Months Ended / June 30, 2026 | Three Months Ended / June 30, 2025 | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|---|---|
| Income tax expense | 18 | 16 | 29 | 24 |
| Net loss | $(36,358) | $(20,765) | $(55,988) | $(33,914) |
| Net loss per share of common stock, basic and diluted | $(0.83) | $(1.92) | $(1.75) | $(3.18) |
| Weighted average common shares outstanding | 43,602,044 | 10,829,760 | 31,919,388 | 10,673,200 |
| Comprehensive loss: | ||||
| Net loss | $(36,358) | $(20,765) | $(55,988) | $(33,914) |
| Other comprehensive loss: | ||||
| Unrealized loss on investments, net | (577) | (34) | (651) | (34) |
Item 1. Financial Statements.
FAQ
- What is Avalo Therapeutics's shares (diluted)?
- Avalo Therapeutics (AVTX) reported shares (diluted) of 43.6M in Q2 2026.
- How has Avalo Therapeutics's shares (diluted) changed year-over-year?
- Avalo Therapeutics's shares (diluted) increased by 302.6% year-over-year, from 10.8M to 43.6M.
- What does shares (diluted) mean?
- The weighted-average shares outstanding plus all potentially dilutive shares from stock options, RSUs, convertible securities, and warrants, using the treasury stock method.
Ask your AI about Avalo Therapeutics's shares (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude